bromopyruvate has been researched along with Pulmonary Arterial Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J; Qi, XM; Sha, YH; Wang, L; Wang, W; Yang, T | 1 |
| Guo, Y; He, Y; Liu, X; Ouyang, F; Qiu, H; Zhang, Y | 1 |
2 other study(ies) available for bromopyruvate and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation.
Topics: Animals; Apoptosis; Blood Pressure; Blotting, Western; Cytochromes c; Fluorescent Antibody Technique; Glycolysis; Immunohistochemistry; In Situ Nick-End Labeling; Inflammation; Male; Monocrotaline; Pulmonary Arterial Hypertension; Pyruvates; Rats; Rats, Sprague-Dawley | 2020 |
3-Bromopyruvate ameliorates pulmonary arterial hypertension by improving mitochondrial metabolism.
Topics: Animals; Disease Models, Animal; Male; Mitochondria; Monocrotaline; Myocytes, Smooth Muscle; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyruvates; Rats; Rats, Sprague-Dawley; TOR Serine-Threonine Kinases | 2020 |